The U.S. Food and Drug Administration (FDA) revised the boxed warning on the label for Metformin Hydrochloride, effective 2026-06-09. This revision specifically addresses the risk of lactic acidosis, detailing serious postmarketing adverse events associated with the drug.
Background
Metformin Hydrochloride is a widely used medication. The boxed warning revision focuses on the serious risk of lactic acidosis, a known adverse effect associated with metformin use. This condition has been linked to severe outcomes, including death, hypothermia, hypotension, and resistant bradyarrhythmias, as noted in postmarketing cases.
What this means
The revision of the boxed warning for Metformin Hydrochloride underscores the critical importance of monitoring for lactic acidosis in patients. Clinicians should be aware of the updated language detailing the severe manifestations observed in postmarketing cases, including death, hypothermia, hypotension, and resistant bradyarrhythmias. This update serves to reinforce the need for careful patient selection, monitoring for risk factors, and prompt recognition and management of lactic acidosis symptoms to mitigate potential adverse outcomes.
Source
This information regarding the revised boxed warning for Metformin Hydrochloride was obtained from the U.S. Food and Drug Administration (FDA) label revision, effective 2026-06-09. The details are available on the DailyMed website, hosted by the National Library of Medicine (NLM) at dailymed.nlm.nih.gov.